Oppenheimer Lifts Target on Celldex Therapeutics (CLDX) on CDX-011 Potential

Oppenheimer boosted its price-target on Outperform-rated Celldex Therapeutics (NASDAQ: CLDX) from $6 to $8 based on a more detailed analysis of CDX-011.

"As a reminder, interim results for the EMERGE study of CDX-011 were reported in May," the analysts notes. "Assuming that the final results in December are consistent with the interim data, we anticipate significant partner interest in this compound."

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $6.38 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• American International Group (AIG) PT Raised to $89 at Piper Sandler
• Celldex (CLDX) Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria